Palindromic Rheumatism

Cross-source consensus on Palindromic Rheumatism from 1 sources and 4 claims.

1 sources · 4 claims

Risks & contraindications

Palindromic rheumatism involves recurrent short attacks of joint pain and swelling without residual joint damage. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
A substantial proportion of people with palindromic rheumatism later develop rheumatoid arthritis. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
Most series estimate that 30-60% of people with palindromic rheumatism progress to rheumatoid arthritis. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
Seropositive palindromic rheumatism may sometimes represent a preclinical rheumatoid arthritis state. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial